Nymox Pharmaceutical is focused on researching and developing novel drugs and diagnostic products for the aging population. NX-1207, the company’s lead drug candidate, is a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH) that is currently in Phase 3 trials in the U.S. The company also has other new developing drug products in such areas as cancer, infectious disease and neurodegenerative diseases. For more information, visit the company’s Web site at www.nymox.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: